Best Life Sciences Companies in Virginia, United States

Developer of therapeutic drugs for acute inflammatory and rare diseases. The company's EPICC peptides are based on research into the human astrovirus, HAstV-1, which causes a non-inflammatory, self-limiting gastroenteritis unique among viruses by inhibiting components of the innate immune system. The company’s pipeline is led by RLS-0071, for the treatment of acute exacerbations of chronic obstructive pulmonary disease and acute graft-versus-host disease.

Funding rounds

• Apr 2026Series C$40M
• Dec 2024Series B$25M
• Feb 2023Series B$29.9M
• Apr 2021Series A$20M

Founders & team

Neel KrishnaCo-FounderKenji CunnionCo-FounderHoward BermanCEO

Investors

Marathon Pharma

Developer of therapeutics for hematologic diseases. The company is focused on developing oral Hemoglobin S polymerization inhibitors that can provide profound disease-modifying clinical benefits of sickle cell disease.

Funding rounds

• Apr 2026Series A$13M
• Mar 2025Seed—
• Jan 2021Grant (prize money)$1.9M
• Aug 2020Grant (prize money)$2.2M

Founders & team

Andrew FleischmanCo-Founder & CEOMartin SafoCo-Founder & CSO

Investors

Zynext Ventures, HHS

Developer of small molecule-based therapeutics for the treatment of CNS and dermatology diseases. The company's lead product candidate QRX001 acts as an antagonist of the N-methyl-D-aspartate receptor (NMDA) and is used for the treatment of post-surgical pain. Another product of the company QRX002 which also acts as an NMDA receptor antagonist used for the treatment of suicidal ideation in military veterans with PTSD.

Funding rounds

• Oct 2025Post IPO$105.3M
• Mar 2021Post IPO—
• Oct 2020Post IPO$710K

Founders & team

Michael MyersCo-Founder Quoin PharmaceuticalsDenise CarterCo-Founder

Investors

Altium Capital Management

Tech stack

Acquia Cloud PlatformAcquia Cloud Site FactoryAdobe AnalyticsAdobe Experience Platform Identity ServiceAdobe Experience Platform LaunchAkamai

TearSolutions develop topical therapeutics for the treatment of dry eye disease. Its lead product is a proprietary synthetic fragment of the protein lacritin. The company claims that Lacripep is equipotent with natural lacritin and can alleviate dry-eye symptoms for up to 16 hours. Its currently in phase I clinical trials.

Developer of therapeutics for cardio-metabolic disorders. The company's lead candidate HU6 is a controlled metabolic accelerator for the treatment of type 2 diabetes, severe hypertriglyceridemia, non-alcoholic steatohepatitis, and heart failure with preserved ejection fraction.

Funding rounds

• Jan 2025Series B$57M
• Aug 2024Series B$66M
• Sep 2022Series B$132M
• Jun 2021Series A$35M

Founders & team

Allen CunninghamCEO

Investors

Longitude Capital, Medicxi, RxCelerate, RA Capital Management, Bain Capital Life Sciences, BB Biotech

Allergen expertise: purified allergens, test kits, testing services, and contract research. This company specializes in manufacturing highly purified proteins and immunoassays for research and diagnostics. Recognized as a world leader in assessment of environmental exposure to allergens, they combine academic expertise with practical experience. They offer a broad range of products and services, including purified allergens, advanced test kits, environmental and food allergen testing, and contract research for specialized needs. The company serves diverse markets, including pharma, diagnostics, academic and government researchers, cleaning and consumer product R&D, industrial hygiene, indoor air quality, and foods. Their offerings include testing services for dust and air allergens, endotoxins, enzymes, food allergens, lab animal allergens, mass spectrometry, cytokine analysis, western blotting, and viral immunoassays. They also provide biomanufacturing and preclinical CRO services. The company is committed to R&D and offers direct contact with their scientific team, fostering flexible, collaborative relationships.

Funding rounds

• Sep 2025Grant (prize money)$8.8M
• Jul 2020Grant (prize money)—
• Aug 2011Grant (prize money)$8M
• Aug 2009Grant (prize money)$8M

Founders & team

Martin ChapmanChief Executive Officer

Investors

Gov, HHS, Bioinnovation Centre, Blocore

Tech stack

AlgoliaAmazon S3Amazon Web ServicesApache Http ServerBootstrapCloudflare

Developer of therapeutics, nutritionals, and informatics tools for inflammation and metabolic diseases. It integrates nutrition, therapeutics, and IT to develop interventions for preventing and treating autoimmune and metabolic diseases. It offers pharmaceutical drug innovation for treating inflammation and diabetes, along with medical foods and supplements. It also provides precision medicine technology. The company conducts preclinical pig studies and offers computational services.

Funding rounds

• Dec 2025Grant (prize money)$1.1M
• Aug 2025Grant (prize money)$314.4K
• Jun 2025Grant (prize money)$359.6K
• Feb 2025Grant (prize money)$347.6K

Founders & team

Josep Bassaganya-RieraCEO

Investors

Center for Innovative Technology, HHS, Design Technologies

Tech stack

ExpressionenginePhpCodeigniterApache Http ServerJquery CdnJquery

Provider of a platform for localized drug delivery system. The company product can be used for drug delivery in the human vascular system.

Developer of a male contraceptive hydrogel device. The ADAM is a non-surgical, non-hormonal, and reversible birth control for men. It isultrasound-visible polymer solution that is injected into the vas deferens. Echo-V& forms a hydrogel device that acts as a semi-permeable membrane, blocking sperm while allowing fluids through.

Funding rounds

• Sep 2025Grant (prize money)$1.4M
• Sep 2024Grant (prize money)$291.4K
• Nov 2022Series A$7.2M
• Oct 2021Series A$10.7M

Founders & team

Kevin EisenfratsCo-Founder & CEO

Investors

i.Lab, Google Ventures, Rhia Ventures, ShangBay Capital, Amboy Street Ventures, MBX Capital

Tech stack

ContentfulCore-JsGatsbyGoogle AnalyticsGoogle WorkspaceHsts

Provider of molecular rotational resonance spectroscopy technology. It offers novel analytical instruments for direct, quantitative analyses of VOCs (volatile organic compounds) in a complex mixture, and for chiral analysis. It also offers analytical services by using the BrightSpec FT-MRR spectrometer platforms. It involves in pharmaceutical small molecule discovery and process R&D groups, fine chemicals solution providers, and academic and government research organizations.

Funding rounds

• Jul 2025Grant (prize money)$1.2M
• Apr 2025Series C$3.9M
• Mar 2025Grant (prize money)$1.6M
• Mar 2023Grant (prize money)$1.7M

Founders & team

Dave McdanielCo-founder and Chief Software Officer

Investors

Seedfund, University of Virginia, Medvest Capital, Genoa Ventures, Arboretum Ventures, Capital Growth Medvest

Tech stack

Hubspot Cms HubHubspotJqueryCloudflare Bot ManagementHstsCloudflare

Developer of 3D-printed implants for treating joint injuries. The implant is designed to replace lost and damaged cartilage and also helps in generating new tissue growth. It uses 3D printing technology and biomaterials to develop the implant as a medical device that is both an orthopaedic load-bearing implant as well a tissue growth scaffold.

Funding rounds

• Dec 2025Seed$4.1M
• Nov 2023Seed—
• Aug 2023Seed$4M
• Dec 2021Seed$2M

Founders & team

Nathan CastroCo-Founder and CTOBenjamin HolmesCo-Founder & CEO

Investors

University of Virginia, BICO, cultivate(MD), Alumni Ventures, Mountain State Capital, National Science Foundation

Tech stack

AstraCart FunctionalityCloudflareCloudflare Bot ManagementComplianzCore-Js

Developer of technology for molecular breast imaging. It has developed smart devices & technology for breast-specific gamma imaging and provides early detection of breast cancer when mammograms are inconclusive & the MBI procedure is an adjunct to mammography for women with dense breasts, questionable mammograms, implants, etc. It provides products in diagnostic imaging, interventional imaging for MBI guided biopsy, and surgical imaging with 3D SPECT.